Middle East & Africa Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User

List of Tables

The Middle East & Africa glioma treatment market is expected to grow from US$ 127.60 million in 2022 to US$ 243.45 million by 2030. It is estimated to grow at a CAGR of 8.4% from 2022 to 2030.

Increasing Drug Approval for Glioma Treatment Fuels Middle East & Africa Glioma Treatment Market

In recent years, there has been a notable increase in the approval of drugs to treat gliomas, marking a significant step forward in addressing the challenges posed by these severe brain tumors. Growing awareness of the urgent need for effective therapeutic options and the dedicated efforts of researchers and pharmaceutical companies to develop innovative treatments are leading to the development and approval of these drugs. Targeted therapies have been a key focus of researchers working on glioma treatment, wherein drugs are designed to specifically target molecular alterations or signaling pathways crucial for glioma cells' survival and growth. These therapies aim to disrupt the tumor's ability to expand while sparing healthy brain tissue. In June 2022, the FDA approved two targeted therapy drugs to be taken in combination-Dabrafenib and Trametinib. These drugs attack the cancerous cells that have undergone the BRAF mutation. The drugs stop the mutated cells from sending growth signals to other cells.

Drug manufacturers have been emphasizing the use of cutting-edge technologies. Kiyatec's ex vivo 3D cell culture technology for high-grade glioma received new clinical data at ASCO 2022. Thus, an increasing number of drug approvals for treating glioma would result in notable growth trends in the glioma treatment market in the near future.

Middle East & Africa Glioma Treatment Market Overview

The UAE, Saudi Arabia, and South Africa are important countries in the Middle East & Africa. The UAE accounts for the largest share of the glioma treatment market in this region. The market is driven by extensive medical studies undertaken by several research institutes, and the availability of infrastructure and facilities for providing brain tumor treatment in the UAE and Saudi Arabia. The UAE serves vital growth opportunities for the healthcare diagnostics business. It has a leading healthcare sector among all Arab countries, which continuously seeks ways to embrace sustainable operations through economic development. Further, government initiatives to encourage research and development, and increase in healthcare expenditure benefit the glioma treatment market in the UAE. Many international glioma treatment market players are entering the South African marketplace to expand their businesses and reach a larger customer base directly. Other major countries contributing to the glioma treatment market growth in the Middle East & Africa, which have been focusing on improving their healthcare infrastructure by allowing new market players to enter into their healthcare markets.

Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Glioma Treatment Market Segmentation

The Middle East & Africa glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the Middle East & Africa glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the Middle East & Africa glioma treatment market in 2022.

Based on treatment type, the Middle East & Africa glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the Middle East & Africa glioma treatment market in 2022.

Based on grade, the Middle East & Africa glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the Middle East & Africa glioma treatment market in 2022.

Based on end user, the Middle East & Africa glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the Middle East & Africa glioma treatment market in 2022.

Based on country, the Middle East & Africa glioma treatment market is segmented int o Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa dominated the Middle East & Africa glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Middle East & Africa glioma treatment market.

Product Code: BMIRE00029269

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East & Africa Glioma Treatment Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Government Funding for Glioma Treatment
- 4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
- 4.3.1 Advancements in Healthcare Sector in Emerging Economies
4.4 Future Trends
- 4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:

5. Middle East & Africa Glioma Treatment Market - Middle East & Africa Market Analysis

5.1 Middle East & Africa Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

6.1 Overview
6.2 Middle East & Africa Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
- 6.3.1 Overview
- 6.3.2 Astrocytoma: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
- 6.4.1 Overview
- 6.4.2 Oligoastrocytoma: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
- 6.5.1 Overview
- 6.5.2 Oligodendroglioma: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

7.1 Overview
7.2 Middle East & Africa Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
- 7.3.1 Overview
- 7.3.2 Surgery: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
- 7.4.1 Overview
- 7.4.2 Chemotherapy: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
- 7.5.1 Overview
- 7.5.2 Radiation Therapy: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

8.1 Overview
8.2 Middle East & Africa Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
- 8.3.1 Overview
- 8.3.2 Low Grade: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 Grade I: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Grade II: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
- 8.4.1 Overview
- 8.4.2 High Grade: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.1 Grade III: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.2 Grade IV: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 Middle East & Africa Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
- 9.3.1 Overview
- 9.3.2 Hospital & Clinics: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: Middle East & Africa Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. Glioma Treatment Market - Middle East & Africa Analysis

10.1.1 Overview
10.1.2 Middle East & Africa Glioma Treatment Market, by Country
- 10.1.2.1 Saudi Arabia
  - 10.1.2.1.1 Saudi Arabia: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  - 10.1.2.1.2 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by Disease
  - 10.1.2.1.3 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by Treatment Type
  - 10.1.2.1.4 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by Grade
  - 10.1.2.1.4.1 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by Low Grade
  - 10.1.2.1.4.2 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by High Grade
  - 10.1.2.1.5 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by End User
- 10.1.2.2 South Africa
  - 10.1.2.2.1 South Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  - 10.1.2.2.2 South Africa: Middle East & Africa Glioma Treatment Market, by Disease
  - 10.1.2.2.3 South Africa: Middle East & Africa Glioma Treatment Market, by Treatment Type
  - 10.1.2.2.4 South Africa: Middle East & Africa Glioma Treatment Market, by Grade
  - 10.1.2.2.4.1 South Africa: Middle East & Africa Glioma Treatment Market, by Low Grade
  - 10.1.2.2.4.2 South Africa: Middle East & Africa Glioma Treatment Market, by High Grade
  - 10.1.2.2.5 South Africa: Middle East & Africa Glioma Treatment Market, by End User
- 10.1.2.3 UAE
  - 10.1.2.3.1 UAE: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  - 10.1.2.3.2 UAE: Middle East & Africa Glioma Treatment Market, by Disease
  - 10.1.2.3.3 UAE: Middle East & Africa Glioma Treatment Market, by Treatment Type
  - 10.1.2.3.4 UAE: Middle East & Africa Glioma Treatment Market, by Grade
  - 10.1.2.3.4.1 UAE: Middle East & Africa Glioma Treatment Market, by Low Grade
  - 10.1.2.3.4.2 UAE: Middle East & Africa Glioma Treatment Market, by High Grade
  - 10.1.2.3.5 UAE: Middle East & Africa Glioma Treatment Market, by End User
- 10.1.2.4 Rest of Middle East & Africa
  - 10.1.2.4.1 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  - 10.1.2.4.2 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by Disease
  - 10.1.2.4.3 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by Treatment Type
  - 10.1.2.4.4 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by Grade
  - 10.1.2.4.4.1 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by Low Grade
  - 10.1.2.4.4.2 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by High Grade
  - 10.1.2.4.5 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by End User

11. Glioma Treatment Market Industry Landscape

11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
- 11.3.1 Overview
11.4 Inorganic Developments
- 11.4.1 Overview

12. Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Merck & Co Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Sun Pharmaceutical Industries Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Amgen Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Teva Pharmaceutical Industries Ltd
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Pfizer Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Amneal Pharmaceuticals Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Karyopharm Therapeutics Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Biocon Ltd
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms